title: A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice.
abstract: OBJECTIVE
  Escherichia coli Nissle 1917 is a probiotic strain used in the treatment of intestinal immune diseases, including ulcerative colitis. The aim of the present study was to test if this probiotic bacterium can also show systemic immunomodulatory properties after oral administration.
  
  
  METHODS
  The probiotic strain was administered to rats or mice for 2 weeks before its assay in two experimental models of altered immune response, the trinitrobenzenesulphonic acid (TNBS) model of rat colitis, localized in the colon, and the lipopolysaccharide (LPS) model of systemic septic shock in mice. Inflammatory status was evaluated both macroscopically and biochemically after 1 week in the TNBS model or after 24 h in the LPS shock model. In addition, splenocytes were obtained from mice and stimulated, ex vivo, with concanavalin A or LPS to activate T or B cells, respectively, and cytokine production (IL-2, IL-5 and IL-10) by T cells and IgG secretion by B cells measured.
  
  
  RESULTS
  E. coli Nissle 1917 was anti-inflammatory in both models of altered immune response. This included a reduction in the pro-inflammatory cytokine tumour necrosis factor-alpha both in the intestine from colitic rats, and in plasma and lungs in mice treated with LPS. The systemic beneficial effect was associated with inhibited production of the T cell cytokines and by down-regulation of IgG release from splenocyte-derived B cells.
  
  
  CONCLUSIONS
  The anti-inflammatory effects of E. coli Nissle 1917 given orally were not restricted to the gastrointestinal tract.
authors.affiliation: Centro de Investigaciones Biomédicas en Red - Enfermedades Hepáticas y Digestivas (CIBER-EHD), Department of Pharmacology, Center for Biomedical Research, University of Granada, Granada, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Arribas
authors.forename: M E
authors.initials: ME
authors.lastname: Rodríguez-Cabezas
authors.forename: D
authors.initials: D
authors.lastname: Camuesco
authors.forename: M
authors.initials: M
authors.lastname: Comalada
authors.forename: E
authors.initials: E
authors.lastname: Bailón
authors.forename: P
authors.initials: P
authors.lastname: Utrilla
authors.forename: A
authors.initials: A
authors.lastname: Nieto
authors.forename: A
authors.initials: A
authors.lastname: Concha
authors.forename: A
authors.initials: A
authors.lastname: Zarzuelo
authors.forename: J
authors.initials: J
authors.lastname: Gálvez
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D002478:Cells, Cultured; D004926:Escherichia coli; D005260:Female; D018836:Inflammation Mediators / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000633:toxicity; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D012772:Shock, Septic / Q000139:chemically induced / Q000473:pathology* / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018836:Inflammation Mediators; D008070:Lipopolysaccharides